// App-Quantinova.ai

522 : A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors

Researchers

Presenter

  • Sha Li

Principal Investigators

  • Ashley Newcombe

  • Kathryn Gilrory

  • Neil Robertson

  • Xue Lei

  • Darren Finlay

  • Karina Barbosa

  • Helen Stewart

  • John Cole

  • Maria Terradas Terradas

  • Loveena Rishi Delori

  • Lynn McGarry

  • Claire McKeeve

  • Claire Reid

  • William Clark

  • Joana Campos

  • Kristina Kirschner

  • Andrew Davis

  • Jonathan Lopez

  • Jun-Ichi Sakamaki

  • Jennifer Morton

  • Kevin Ryan

  • Stephen Tait

  • Sheela Abraham

  • Tessa L. Holyoake

  • Brian Higgins

  • Xu Huang

  • Karen Blyth

  • Mhairi Copland

  • Timothy Chevassut

  • Aniruddha J. Deshpande

  • Karen Keeshan

  • Peter Adams

Medical Centers

  • Sanford Burnham Prebys Medical Discovery Institute, Heidelberg, CA

  • University of Glasgow, Glasgow, United Kingdom

  • Sanford Burnham Prebys Medical Discovery Institute, Heidelberg, CA

  • University of Sussex, London, United Kingdom

  • Cancer Research UK Beatson Institute, Glasgow, United Kingdom.

  • Queen Elizabeth University Hospital, Glasgow, United Kingdom

  • Queen's University, ON, Canada

  • Roche Innovation Center, New York, NY

Locations

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Mouse double minute 2 homolog

  • BCL2 Binding Component 3

  • Tumor protein p53

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved